Summary Recent preclinical and clinical data suggest that TP53 status and TP53 mutations may be important in determining tumour aggressiveness and therapy response. In this study we investigate the feasibility of a structural and quantitative analysis of TP53 on fineneedle aspiration (FNA) material obtained from 31 consecutive female patients with breast carcinoma, enrolled in a primary chemotherapy protocol. Tumours were screened for p53 protein overexpression and TP53 mutations (exons 5-8) using immunocytochemistry, polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and DNA sequencing analyses, and finally using fluorescence in situ hybridization (FISH) analysis. Positive nuclear staining was identified in six cases whereas mutations were detected in nine. Although the immunoreactive pattern fitted fully with the characterized TP53 mutation type, the considerable number of null p53 mutations (i.e. four) coupled with the lack of information regarding the localization of TP53 mutations make immunocytochemistry an inadequate indicator of TP53 function deregulation. Combining molecular and FISH analyses, we detected three cases with TP53 deletion and one case with deletion and mutation. Finally, DNA static-image analysis performed on 29 cases showed aneuploidy in 26 cases, which included all TP53-mutated cases. The present results show that FNA may assist clinical decisions by allowing the evaluation of a variety of biological parameters relevant for prognosis and treatment planning.
The fine-needle aspiration (FNA) technique represents one of the most effective and versatile methodologies that contribute to the diagnosis and the management of breast cancer. Over recent years, the field of FNA application has expanded, and currently FNA spans the diagnostic assessment of palpable and non-palpable nodules and contributes to management decisions at surgical and medical levels (Masood et al, 1990; Layfield, 1992) . In fact, FNA has largely replaced frozen sections and, in cases candidated to primary chemotherapy, provides hormonal receptor assessment as well as other useful pathobiological parameters with an efficiency that equals that of histology (Thomas et al, 1990; Dowell et al, 1994; Leong et al, 1996) .
Recent clinical evidence supports a critical role of TP53 status in providing prognostic information (Kovach et al, 1996; Sjogren et al, 1996) . Preclinical (Lowe et al, 1993 (Lowe et al, , 1994 Wahl et al, 1996) and clinical data (Bergh et al, 1995; Aas et al, 1996; Fricker, 1996; Sjogren et al, 1996) suggest that TP53 status and TP53 mutation types may be important not only in determining tumour aggressiveness but also in the response to therapy. In fact, there is increasing evidence that tumours lacking normal TP53 function are clinically more aggressive as they acquire a selective growth advantage becoming more resistant to ionizing radiations and some widely used anti-cancer drugs.
Here, we investigate the feasibility of an extensive structural and quantitative analysis of the TP53 gene using PCR-SSCP and sequencing, FISH, together with DNA static-image analyses on FNA material obtained from patients with clinical features matching primary chemotherapy criteria.
The present results show that FNA may further assist clinical decisions by allowing a simultaneous evaluation of a variety of biological parameters relevant for prognosis and by supplying precise molecular data that are important in treatment planning. This is of particular value in a primary chemotherapy setting, as complete tumour regression may occur and FNA-based prechemotherapy information may represent the only available information unaffected by therapy.
MATERIALS AND METHODS
Patients and materials Thirty-one consecutive female patients (age range 25-71 years, mean 53 years) with primary breast carcinoma examined by FNA who entered a primary chemotherapy protocol (doxorubicin and paclitaxel) were chosen for the present study. According to the Tumour Node and Metastases (TNM) classification (UICC, 1992;  (Frigo et al, 1995) and of bcl2 protein by Mab bcl-2, 124 diluted 1:100 (Dako) as detailed above. Overall, hormonal receptor-positive cases accounted for 36% (12 out of 31). Bcl2 expression was highly associated with hormonal receptor positivity: all receptorpositive cases were bcl2 positive; nonetheless, 20% of receptornegative cases were bcl2 positive (Alsabeh et al, 1996) . All but one (case no. 24) of the bcl2-positive cases were p53 negative.
DNA analysis
Five-hundred-microlitre aliquots of PBS cell suspension were digested by proteinase K (0.6 gl of 10 mg ml-' proteinase K per 100 gl of cell suspension) and submitted to phenol extractions following standard procedures.
Exons 5-8 were initially amplified by nested PCR amplification (primer sequences are available upon request). A 1-pl aliquot of the amplification products diluted 1:100 was used as DNA template for single-strand conformation polymorphism analysis (SSCP), as described by Donghi et al (1993) . PCR-amplified exons showing abnormal SSCP migration were subjected to direct DNA sequencing using the AmpliCycle Sequencing kit (PerkinElmer Cetus, Branchburg, NJ, USA). For sequencing assays, genomic DNA was amplified by nested PCR as for SSCP analysis. Amplified fragments were purified on 2% low-melting-point agarose gels. The purified DNA fragments were used directly for sequence analysis. Each sequence reaction was performed at least twice, analysing separate amplifications.
Dual-colour FISH Thirty-one FNA samples were analysed: three were frozen smears, one was a cytospin from frozen material in PBS suspension, four were archival cytological smears stained with May GriinwaldGiemsa (MGG) and the remaining were Papanicolaou (PAP)-stained smears. Archival cytological smears stained with PAP or MGG were destained and treated before in situ hybridization, essentially according to Cajulis et al (1996) . The biotinylated probe p53 (TP53) (Oncor, Gaithersburg, MD, USA) was cohybridized with the digoxigenin-labelled chromosome 17 a-satellite (D17Z1) (Oncor) according to Lichter et al (1990) and the manufacturer's recommendations. The biotinylated probe p53 was detected by two layers of avidin-FITC (Vector), and chromosome 17 a-satellite by one layer of rhodamine-labelled anti-digoxigenin (ab) (Boehringer Mannheim). Slides were then counterstained by DAPI (4,6-diamidino-2-phenylindole dihydrochloride hydrate). The slides were observed at 1000 x magnification. At least 100 well-defined nuclei were analysed for each hybridization. The sample was scored as deleted or polysomic only when at least 30% of the considered cells showed deletion of TP53 or polysomy of chromosome 17, as false monosomies or deletions could be due to insufficient hybridization efficiency (Sauter et al, 1996) . Images were acquired with a cooled CCD camera (Photometrics, Tucson, AZ, USA) coupled to a Zeiss fluorescence microscope and controlled by a Power Macintosh 710/800. Frames of the nuclei were taken separately using the IPLab Spectrum (Signal Analytics) software package; the images were then pseudocoloured and merged using the Gene Join software (Ried et al, 1992) .
DNA content image analysis (IA)
For IA MGG-stained smears were used: coverslips were removed with xylene and smears destained with 1% hydrochloric acid in 70% ethanol, refixed in 10% neutral formalin for 1 h and then Feulgen stained according to the directions of the ESACP Consensus Meeting (Bocking et al, 1995) . Briefly, after hydrolysis in SN hydrochloric acid 22°C for 1 h, specimens were rinsed in distilled water for 5 min, stained in basic fuchsin Schiff-Feulgen reagent at 25°C for 60 min, rinsed in running water and then in freshly prepared sulphur dioxide. The specimens were then dehydrated in ethanol and xylene and mounted in coverslipping resin. Ploidy analysis was performed using the Cires-Vidas imaging system (Zeiss, Kontron Elektronik, Oberkochen, Germany).
From 180 to 221 cancer cells were examined, and at least 50 diploid rat hepatocytes were used as an extemal standards reference for each case.
Results of the cytophotometric DNA measurements, on the basis of the obtained histograms, were expressed as diploid and aneuploid. For each case, the malignancy index (MI) was calculated as the product of 2c deviation index (2cDI) per Sc exceeding rate (ScER) (Bocking et al, 1984 ) (data not shown).
RESULTS
The obtained results are reported in Table 1 .
Morphology
Morphological diagnosis was consistent with breast carcinoma in all cases.
Cytological grading, performed according to a modified (reverse) Black's scheme (Fisher et al, 1980) , yielded the following distribution: grade I, 1 out of 31 cases (3.2%); grade II, 9 out of 31 cases (29%); grade III, 21 out of 31 cases (67.7%).
Immunocytochemistry (ICC) p53
Six out of 31 (19%) cases tumed out to be p53 reactive with the number of immunostained nuclei exceeding 70% in all cases. MIB 1 High MIB1 immunostaining (> 30%) was identified in 26 out of 29 cases (89%).
MIB1 vs cytological grading
In all but one G3 (18 out of 19 cases, 94%) and in all but one G2 (eight out of nine, 88%), a high immunostaining was observed. The GI case (case no. 22) showed a low MIB1 immunostaining (<10%). In two cases (case nos. 12 and 15), MIBI immunostaining was not evaluable.
Frequency and spectrum of p53 gene mutations
Nested PCR-SSCP analysis of exons 5-8 was performed successfully on all the 31 cases included in this study. Eleven tested tumours showed an abnormal SSCP pattern and were all confirmed as mutated by direct DNA sequencing. Table 1 shows the details regarding the genetic changes identified by DNA sequencing analysis.
The position and incidence of the mutations were distributed as follows: three mutations were located in exon 5, three in exon 6, three in exon 7, one in exon 8 and one in intron 6. Eight were missense mutations: seven resulted in an amino acid substitution; the remaining one revealed a neutral polymorphism at codon 213, exon 6, which does not result in a change in amino acid sequence (CGA -* CGG, Arg Arg) (Carbone et al, 1991; Elledge et al, 1993; Bems et al; . Missense mutations included six transitions (one at CpG dinucleotides) and two transversions. Six of the seven (86%) amino acid substitutions detected in our series occurred at mutational hotspot codons (codons 175, 194, 220, 245, 248 and 249) located in evolutionary highly conserved regions (Greenblatt et al, 1994) .
Two of the 11 mutations were non-missense mutations, including a 1-bp deletion at codon 176 and a 1-bp insertion at codon 176. Both these situations change the translation frame and lead to the appearance of a premature stop codon, resulting in an early chain termination during translation. Furthermore, in one case, a base substitution was found at 15 bp downstream of the 3' end of exon 6. This intronic alteration, to the best of our knowledge, should not affect TP53 gene expression.
The observed neutral polymorphism at codon 213 (case no. 29) and intronic base substitution (case no. 1) were not recorded as mutations in the correlations specified below of molecular data with cytological grading, ICC and IA analysis data.
Molecular analysis vs cytological grading
Eight out of the nine (88%) mutated cases and 13 out of the 22 (59%) wild-type cases showed high nuclear grade (G3), indicating a significant association (Table 1 ).
Molecular analysis vs ICC
p53 immunoreactivity correlated with the type of gene mutation. All but one (83%) of the ICC-positive cases presented a missense mutation that leads to an amino acid change; only one case (no. 6) had a wild-type p53 gene. The ICC-negative cases included a deletion, an insertion and only one missense mutation. The association between missense mutations and ICC was statistically significant (P = 0.0007, Fisher's exact test).
FISH analysis
Seventeen cases were evaluable for both TP53 and chromosome 17 content, seven only for TP53 content and seven were not evaluable at all. Chromosome 17 pericentromeric signals were detectable in only 17 slides, this may be due to a problem of fixation and/or conservation of the slides before FISH. Moreover, p53 probe was detected with two layers of avidin-FITC as a chromosome 17 a-satellite with only one layer of rhodamine-labelled anti-digoxigenin (ab) to avoid background artifacts.
Four out of 24 cases evaluable for TP53 content showed the deletion of one TP53 allele (cases nos. 19, 20, 25, 28) . One of them was also mutated (case no. 19). Nine out of 17 cases evaluable for chromosome 17 content were polysomic and one was monosomic (data not shown).
DNA (IA)
The analysis was performed on 29 cases. In two cases, insufficient material was available (Table 1) . Twenty-six out of twenty-nine cases (89%) were aneuploid, of which three were hypertetraploid, whereas 3 out of 29 (10%) were diploid.
In the aneuploid tumours, MI ranged from 0.32 to 7759.44 (mean 446.13, median 27.45) (data not shown).
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Comparing ploidy results with molecular data, all cases with TP53 mutations were aneuploid.
IA vs MIB1 and cytological grading
Comparing ploidy results with MIB I immunostaining, 24 out of 26 (92%) aneuploid cases showed a high MIB 1 immunostaining. Furthermore, all aneuploid cases were G3 or G2 with high MIB 1 immunostaining (> 30%).
DISCUSSION
This study shows for the first time, to the best of our knowledge, the feasibility of an extensive structural and quantitative analysis of TP53 on material obtained from FNA. The same material allowed us to perform DNA analysis and compare both molecular, molecular-cytogenetic and DNA content data to a number of routinely used immunocytochemical-based parameters. Although a statistically significant correlation was observed between p53 overexpression and TP53 mutation (P = 0.004), and the observed immunoreactivity pattern fitted fully with the characterized mutation type, the results clearly show a definitively higher informativity of molecular over immunophenotypic analysis. In fact, no ICC reaction was observed in the four cases harbouring TP53 mutations. Two of these false-negative ICC results (case nos. 20 and 26) were generated as a consequence of premature stop codons that determine the synthesis of truncated proteins and thus render ICC detection impossible. In addition, we did not find immunoreactivity in case numbers 30 and 10, despite TP53 missense mutations at codons 248 and 220 respectively. The results observed in case 30 are in agreement with the hypothesis reported by Greenblatt et al (1994) , who observed that mutants at codon 248 (Arg--Trp), implying this particular amino acid change, maintain apparent wild-type conformation by antibody analysis but acquire mutant transactivation function. The discrepancy between ICC and molecular results in case number 10 is difficult to explain as the potential functional significance of this mutation has not yet been verified.
In view of all the above, and taking into consideration the patient selection, the failure of immunophenotyping to detect mutations closely mirrors that observed for histology-based material (Dunn et al, 1993; Aas et al, 1996; Sjogren et al, 1996) . This observation not only indicates that ICC alone is an insufficient and unreliable indicator of p53 gene mutations in breast carcinoma, but also points out a significant agreement between the present FNA-based data and those obtained from conventional histological samples.
In one case (no. 6), molecular results did not coincide with p53-positive immunostaining. This might be due to a mutation localized in exons outside the screening area (exons 5-8). Approximately 10-20% of TP53 gene mutations have been found in exons 1-4 or 9-11 (Soussi et al, 1994; Hartmann et al, 1995) . However, mutations in other genes coding for proteins involved in the p53 pathway (Momand et al, 1992; Righetti et al, 1996) or the presence of p53-interacting proteins may also contribute to p53 stabilization.
Furthermore, DNA sequencing highlighted that seven out of ten mutations, three of which showed no immunoreactivity, affected the central part of the gene, which includes the zinc-binding domains L2 (codons 163-195) and L3 (codons 236-251).
TP53 molecular and FISH analyses were successfully combined, allowing the detection of four cases with deletion of one TP53 allele; three of them presented, therefore, only one TP53 normal allele and are, in case of a subsequent TP53 mutation, at higher risk of p53 loss of function. The remaining case presented both deletion and mutation (Figure 1 ), which, with the homozigous mutation, represents the most tumorigenic situation (Solomon et al, 1991) . In this particular situation, the significance of the presence of only p53-mutated protein in tumour cells has not yet been fully explored. A possible anomalous transactivating activity of p53-mutated complexes might confer a different biological behaviour to the affected cells. The present approach could potentially reveal more such cases; further analysis would clarify this point.
The rationale for comparing TP53 alterations with DNA analysis stems from the in vitro and in vivo evidence showing that loss, or inactivation, of TP53 can be associated with unstable tetraploid cells that are predisposed for the development of aneuploid populations (Cross et al, 1995) . Although in the present series, 17 DNA aneuploid cases showed no TP53 mutations, indicating the possibility of redundant control mechanisms for genetic stability, it is worth mentioning that all nine cases harbouring TP53 mutations showed aneuploid DNA content, and two out of three hypertetraploid cases belonged to the TP53-mutated cases. Furthermore, the results support a close correlation between aneuploidy, high MIB 1 value, high cytological grade and show that MIB 1 may usefully complement grading by contributing to a more accurate definition of the grey zone represented by grade II and may positively affect cytological diagnosis (Pinder et al, 1995) . In fact, similarly to grade III, all grade II cases with a high MIB 1 value fell within the aneuploid group.
In conclusion, molecular analysis appears to be mandatory to acquire more precise information, not only regarding the type of TP53 mutation but also the TP53 genomic status for the discrimination between wild-type-mutant complexes (dominant-negative effect) and mutant-mutant proteins, which could confer different biological properties to the tumour cells; FNA seems to be suitable for this type of study. Complementary DNA analysis stresses the strong predictivity of aneuploidy for grading either represented as grade III or grade II and critically supplemented by ICC-MIB1 assessment.
The results demonstate that PCR-SSCP and sequencing, FISH and DNA image analyses can be simultaneously and successfully performed on FNA material, making FNA a reliable and helpful tool for the prognostic assessment and the therapeutic management of breast cancer patients.
